Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867)

Tonghua Dongbao Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	2,286	2,930	2,742	3,219	2,855	2,752
Other Revenue	145.81	145.81	36.47	49.22	37.13	24.7
Revenue	2,432	3,075	2,778	3,268	2,892	2,777
Revenue Growth (YoY)	-12.24%	10.69%	-14.98%	12.99%	4.14%	3.13%
Cost of Revenue	547.28	621.05	628.13	586.99	582.86	727.15
Gross Profit	1,884	2,454	2,150	2,681	2,309	2,050
Selling, General & Admin	1,207	1,047	1,114	1,255	1,091	1,006
Research & Development	114.21	104.96	146.71	166.86	106.93	78.04
Other Operating Expenses	9.25	11.65	14.57	11.27	-34.35	18.49
Operating Expenses	1,326	1,184	1,268	1,435	1,165	1,108
Operating Income	558.16	1,270	882.29	1,246	1,145	942.39
Interest Expense	-13.95	-5.17	-0.28	-	-10.17	-20.56
Interest & Investment Income	129.62	103.61	942.66	304.32	43.64	47.3
Currency Exchange Gain (Loss)	0.47	0.47	0	0.24	-0.45	0
Other Non Operating Income (Expenses)	-1.35	-1.65	-0.88	0.33	-7.38	-2.07
EBT Excluding Unusual Items	672.96	1,368	1,824	1,550	1,170	967.06
Gain (Loss) on Sale of Investments	1.48	0.52	0.96	-0.37	0.37	-
Gain (Loss) on Sale of Assets	12.4	-3.13	-0.11	-13.48	-62.44	2.22
Asset Writedown	-70.49	-7	-1.74	-11.53	-	-3.48
Other Unusual Items	-244.15	7.91	6.62	9.35	-	-13.3
Pretax Income	372.2	1,366	1,830	1,534	1,108	952.5
Income Tax Expense	31.14	197.97	247.69	225.86	177.81	142.85
Earnings From Continuing Operations	341.06	1,168	1,582	1,309	930.32	809.64
Minority Interest in Earnings	0.25	-0.09	0.06	-0.34	-0.41	1.56
Net Income	341.31	1,168	1,582	1,308	929.92	811.21
Net Income to Common	341.31	1,168	1,582	1,308	929.92	811.21
Net Income Growth	-63.66%	-26.17%	20.92%	40.69%	14.63%	-3.27%
Shares Outstanding (Basic)	2,138	1,979	2,002	2,044	2,022	2,028
Shares Outstanding (Diluted)	2,138	1,979	2,002	2,044	2,022	2,028
Shares Change (YoY)	6.93%	-1.15%	-2.04%	1.12%	-0.32%	-0.85%
EPS (Basic)	0.16	0.59	0.79	0.64	0.46	0.40
EPS (Diluted)	0.16	0.59	0.79	0.64	0.46	0.40
EPS Growth	-66.02%	-25.32%	23.44%	39.13%	15.00%	-2.44%
Free Cash Flow	74.51	513.4	370.21	579.62	712.69	859.04
Free Cash Flow Per Share	0.03	0.26	0.18	0.28	0.35	0.42
Dividend Per Share	0.250	0.250	0.500	0.300	0.210	0.200
Dividend Growth	0%	-50.00%	66.67%	42.86%	5.00%	0%
Gross Margin	77.49%	79.81%	77.39%	82.04%	79.85%	73.82%
Operating Margin	22.95%	41.31%	31.75%	38.12%	39.57%	33.93%
Profit Margin	14.04%	37.97%	56.93%	40.03%	32.15%	29.21%
Free Cash Flow Margin	3.06%	16.69%	13.32%	17.74%	24.64%	30.93%
EBITDA	768.43	1,455	1,033	1,389	1,299	1,095
EBITDA Margin	31.60%	47.32%	37.20%	42.51%	44.92%	39.44%
D&A For EBITDA	210.27	184.94	151.17	143.65	154.54	152.8
EBIT	558.16	1,270	882.29	1,246	1,145	942.39
EBIT Margin	22.95%	41.31%	31.75%	38.12%	39.57%	33.93%
Effective Tax Rate	8.37%	14.49%	13.54%	14.72%	16.05%	15.00%
Revenue as Reported	2,432	3,075	2,778	3,268	-	2,777
Advertising Expenses	-	63.59	46.79	143.61	120.46	102.05

Source: S&P Capital IQ. Standard template. Financial Sources.